BioNTech has acquired Chinese cancer drugmaker Biotheus in a near $1bn deal, as the Covid-19 vaccine maker taps into the country’s health sciences expertise to develop promising immunotherapy drugs.
The deal gives the German biotech control of a drug class that has shown potential to outperform Merck’s blockbuster cancer treatment Keytruda, the best-selling drug globally in 2023 with $25bn in sales.
BioNTech will make $800mn in upfront payments to Biotheus, a drugmaker based in Guangdong province, with milestone payments of up to $150mn.
您已阅读18%（541字），剩余82%（2416字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。